{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:01:58Z","timestamp":1790787718980,"version":"4.1.0"},"reference-count":30,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.3892\/ol.2017.6514","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T12:16:37Z","timestamp":1498824997000},"page":"3039-3042","source":"Crossref","is-referenced-by-count":28,"title":["Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: A case report"],"prefix":"10.3892","volume":"14","author":[{"given":"Yasuhiro","family":"Arakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"key":"key20180108114237_b1-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000065838","article-title":"Clinicopathologic features of gastric cancers producing alpha-fetoprotein","volume":"19","author":"Kono","year":"2002","journal-title":"Dig Surg"},{"key":"key20180108114237_b2-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/bjs.7081","article-title":"Long-term results of gastrectomy for alpha-fetoprotein-producing gastric cancer","volume":"97","author":"Inoue","year":"2010","journal-title":"Br J Surg"},{"key":"key20180108114237_b3-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1477-7819-11-246","article-title":"Characteristic analysis of \u03b1-fetoprotein-producing gastric carcinoma in China","volume":"11","author":"Li","year":"2013","journal-title":"World J Surg Oncol"},{"key":"key20180108114237_b4-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/j.1572-0241.1999.01158.x","article-title":"Alpha-fetoprotein-producing gastric cancer: Histochemical analysis of cell proliferation, apoptosis and angiogenesis","volume":"94","author":"Koide","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"key20180108114237_b5-ol-0-0-6514","first-page":"809","article-title":"Angiogenesis of AFP producing gastric carcinoma: Correlation with frequent liver metastasis and its inhibition by anti-AFP antibody","volume":"11","author":"Takahashi","year":"2004","journal-title":"Oncol Rep"},{"key":"key20180108114237_b6-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/or.2015.4528","article-title":"Targeted therapy for gastric cancer: Current status and future directions (Review)","volume":"35","author":"Yuan","year":"2016","journal-title":"Oncol Rep"},{"key":"key20180108114237_b7-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"key20180108114237_b8-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"key20180108114237_b9-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20180108114237_b10-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: A practical approach","volume":"25","author":"R\u00fcschoff","year":"2012","journal-title":"Mod Pathol"},{"key":"key20180108114237_b11-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jso.24096","article-title":"A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03","volume":"113","author":"Okabe","year":"2016","journal-title":"J Surg Oncol"},{"key":"key20180108114237_b12-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/PAS.0b013e31823aafec","article-title":"Histologic and immunohistochemical analyses of \u03b1-fetoprotein-producing cancer of the stomach","volume":"36","author":"Kinjo","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"key20180108114237_b13-ol-0-0-6514","unstructured":"http:\/\/link.springer.com\/article\/10.1245\/s10434-010-0985-4"},{"key":"key20180108114237_b14-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N Engl J Med"},{"key":"key20180108114237_b15-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180108114237_b16-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/jjco\/hyn043","article-title":"A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: A report from the gastrointestinal Oncology group of the Japan clinical oncology group, JCOG 9207 trial","volume":"38","author":"Hamaguchi","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"key20180108114237_b17-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000072332","article-title":"AFP-producing gastric carcinoma: Multivariate analysis of prognostic factors in 270 patients","volume":"65","author":"Adachi","year":"2003","journal-title":"Oncology"},{"key":"key20180108114237_b18-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"key20180108114237_b19-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1200\/JCO.2005.00.992","article-title":"Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence","volume":"23","author":"Mitsudomi","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108114237_b20-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180108114237_b21-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00535-002-1099-y","article-title":"Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein","volume":"38","author":"Kamei","year":"2003","journal-title":"J Gastroenterol"},{"key":"key20180108114237_b22-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jso.1133","article-title":"Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma","volume":"78","author":"Ichikura","year":"2001","journal-title":"J Surg Oncol"},{"key":"key20180108114237_b23-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5230\/jgc.2013.13.1.58","article-title":"Five-year survival of alpha-fetoprotein-producing gastric cancer with synchronous liver metastasis: A case report","volume":"13","author":"Koneri","year":"2013","journal-title":"J Gastric Cancer"},{"key":"key20180108114237_b24-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.3892\/ol.2015.3731","article-title":"Successful multimodal therapy for an \u03b1-fetoprotein-producing gastric cancer patient with simultaneous liver metastases","volume":"10","author":"Fang","year":"2015","journal-title":"Oncol Lett"},{"key":"key20180108114237_b25-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"key20180108114237_b26-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.23214","article-title":"Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2","volume":"50","author":"Blechacz","year":"2009","journal-title":"Hepatology"},{"key":"key20180108114237_b27-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cncr.26255","article-title":"Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma","volume":"118","author":"Edeline","year":"2012","journal-title":"Cancer"},{"key":"key20180108114237_b28-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"key20180108114237_b29-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20180108114237_b30-ol-0-0-6514","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1634\/theoncologist.2014-0006","article-title":"How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer","volume":"19","author":"Kim","year":"2014","journal-title":"Oncologist"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T07:07:25Z","timestamp":1659164845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.6514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,6,30]]},"published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.3892\/ol.2017.6514"],"URL":"https:\/\/doi.org\/10.3892\/ol.2017.6514","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,30]]}}}